Prevalence of past and reactivated viral infections and efficacy of cyclosporine a as monotherapy or in combination in patients with psoriatic arthritis - Synergy study: A longitudinal observational study

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Colombo, Delia ^a   Chimenti, Sergio ^b   Grossi, Paolo ^c   Marchesoni, Antonio ^d   Di Nuzzo, Sergio ^e   Griseta, Vito ^f   Gargiulo, Anna ^g   Parodi, Aurora ^h   Simoni, Lucia ⁱ   Bellia, Gilberto ^a  

^a Novartis Farma Italia ^*  (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d Instituto Ortopedico G Pini   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f MIULLI GENERAL HOSPITAL   (Italy)

^g Azienda Ospedaliera Sant'Anna e San Sebastiano   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ MediData srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CHOLESTEROL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIBODY; ETANERCEPT; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; QUINOLONE DERIVATIVE; RETINOID; SALAZOSULFAPYRIDINE; VIRUS DNA; VIRUS RNA; CYCLOSPORIN; VIRUS ANTIBODY;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CENTRAL VEIN OCCLUSION; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FAINTNESS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GINGIVA BLEEDING; GINGIVA HYPERPLASIA; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HYPERTENSION; HYPOACUSIA; HYPOSMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY COLIC; LIVER FUNCTION TEST; LONGITUDINAL STUDY; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICTURITION DISORDER; MONOTHERAPY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PARVOVIRUS INFECTION; POSTMICTURITION SYNCOPE; PREVALENCE; PROSPECTIVE STUDY; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; PUVA; REACTIVATED VIRAL INFECTION; SENSORY DYSFUNCTION; SEROCONVERSION; SEROLOGY; SIDE EFFECT; SORE THROAT; STOMATITIS; SYSTEMIC THERAPY; TREATMENT DURATION; TREMOR; ULTRAVIOLET B RADIATION; URETHRITIS; URINARY TRACT DISEASE; VARICELLA ZOSTER VIRUS; VEIN OCCLUSION; VIRUS INFECTION; VIRUS REACTIVATION; VISUAL ANALOG SCALE; ARTHRITIS, PSORIATIC; BLOOD; COMPLICATION; DRUG POTENTIATION; EPIDEMIOLOGY; IMMUNOLOGY; INFECTION; ISOLATION AND PURIFICATION; MIDDLE AGED; VIROLOGY; VIRUS;

ADULT; ANTIBODIES, VIRAL; ARTHRITIS, PSORIATIC; CYCLOSPORINE; DRUG SYNERGISM; FEMALE; HUMANS; INFECTION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; VIRUSES;

EID: 84899501901     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/941767     Document Type: Article

References (22)

1. Mease P., Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Current Rheumatology Reports 2006 8 5 348 354 2-s2.0-33750389677 10.1007/s11926-006-0064-9 (Pubitemid 44638827)
2. Salaffi F., de Angelis R., Grassi W., Avaltroni D., Blasetti P., Brecciaroli D., Carotti M., Cerioni A., Ciapetti A., Farina A., Filippucci E., Del Medico P., Garofalo G., Gasparini S., Gutierrez M., Silvestri C. A., Scalini S., Stancati A., Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study. Clinical and Experimental Rheumatology 2005 23 6 819 828 2-s2.0-29944436678 (Pubitemid 43040510)
3. Mease P. J., Psoriatic arthritis: update on pathophysiology, assessment and management. Annals of the Rheumatic Diseases 2011 70 supplement 1 i77 i84 2-s2.0-79953000642 10.1136/ard.2010.140582
4. Love T. J., Zhu Y., Zhang Y., Obesity and the risk of psoriatic arthritis: a population-based study. Annals of the Rheumatic Diseases 2012 71 1273 1277
5. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism 2006 54 8 2665 2673 2-s2.0-33746951437 10.1002/art.21972 (Pubitemid 44205029)
6. Fredriksson T., Pettersson U., Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978 157 4 238 244 2-s2.0-0018099294 (Pubitemid 8387357)
7. Hawker G. A., Mian S., Kendzerska T., French M., Measures of adult pain: visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care and Research 2011 63 supplement 11 S240 S252 2-s2.0-80755127065 10.1002/acr.20543
8. Garrett S., Jenkinson T., Kennedy L. G., Whitelock H., Gaisford P., Calin A., A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. Journal of Rheumatology 1994 21 12 2286 2291 2-s2.0-0028575453
9. Chandran V., Epidemiology of psoriatic arthritis. Journal of Rheumatology 2009 36 2 213 215 2-s2.0-64849103963 10.3899/jrheum.081242
10. Vassilopoulos D., Calabrese L. H., Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology 2007 19 6 619 625 2-s2.0-34948850781 10.1097/BOR.0b013e3282f05b63 (Pubitemid 47530884)
11. Gossec L., Smolen J. S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., Van Der Heijde D., FitzGerald O., Aletaha D., Balint P., Boumpas D., Braun J., Breedveld F. C., Burmester G., Cañete J. D., De Wit M., Dagfinrud H., De Vlam K., Dougados M., Helliwell P., Kavanaugh A., Kvien T. K., Landewé R., Luger T., Maccarone M., McGonagle D., McHugh N., McInnes I. B., Ritchlin C., Sieper J., Tak P. P., Valesini G., Vencovsky J., Winthrop K. L., Zink A., Emery P., European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases 2012 71 1 4 12 2-s2.0-82955236087 10.1136/annrheumdis-2011-200350
12. Ciesek S., Steinmann E., Iken M., Ott M., Helfritz F. A., Wappler I., Manns M. P., Wedemeyer H., Pietschmann T., Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010 138 5 1875 1884 2-s2.0-77951863795 10.1053/j.gastro.2010.02.004
13. Ciesek S., Wedemeyer H., Immunosuppression, liver injury and post-transplant HCV recurrence. Journal of Viral Hepatitis 2012 19 1 1 8 2-s2.0-84355161578 10.1111/j.1365-2893.2011.01548.x
14. Watashi K., Hijikata M., Hosaka M., Yamaji M., Shimotohno K., Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003 38 5 1282 1288 2-s2.0-0142182744 10.1053/jhep.2003.50449 (Pubitemid 37314838)
15. Nakagawa M., Sakamoto N., Tanabe Y., Koyama T., Itsui Y., Takeda Y., Chen C.-H., Kakinuma S., Oooka S., Maekawa S., Enomoto N., Watanabe M., Suppression of hepatitis C virus replication by cyclosporin A is mediated by blockade of cyclophilins. Gastroenterology 2005 129 3 1031 1041 2-s2.0-24144468662 10.1053/j.gastro.2005.06.031 (Pubitemid 41242693)
16. Yang F., Robotham J. M., Nelson H. B., Irsigler A., Kenworthy R., Tang H., Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. Journal of Virology 2008 82 11 5269 5278 2-s2.0-43949123575 10.1128/JVI.02614-07 (Pubitemid 351705235)
17. Levy G., Villamil F., Samuel D., Sanjuan F., Grazi G. L., Wu Y., Marotta P., Boillot O., Muehlbacher F., Klintmalm G., Results of LIS2T, a multicenter, ramdomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004 77 11 1632 1638 2-s2.0-2942696213 10.1097/01.TP.0000129095.51031.42 (Pubitemid 38780525)
18. Levy G., Grazi G. L., Sanjuan F., Wu Y., Mühlbacher F., Samuel D., Friman S., Jones R., Cantisani G., Villamil F., Cillo U., Clavien P. A., Klintmalm G., Otto G., Pollard S., McCormick P. A., 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplantation 2006 12 1464 1472 (Pubitemid 44594275)
19. Miura H., Itoh Y., Matsumoto Y., Tani M., Tanabe N., Isonokami M., Kurachi K., Kozuka T., Long-term administration of cyclosporin A to HCV-antibody-positive patients with dermatologic diseases. International Journal of Dermatology 1999 38 4 310 314 2-s2.0-0032930373 10.1046/j.1365-4362.1999. 00690.x (Pubitemid 29189641)
20. Galeazzi M., Bellisai F., Giannitti C., Manganelli S., Morozzi G., Sebastiani G. D., Safety of cyclosporin A in HCV-infected patients: Experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Annals of the New York Academy of Sciences 2007 1110 544 549 2-s2.0-35748981183 10.1196/annals.1423.058 (Pubitemid 350043044)
21. Giannitti C., Benucci M., Caporali R., Manganelli S., Bellisai F., Sebastiani G. D., Galeazzi M., Efficacy and safety of anti-TNF- α therapy combined with cyclosporine a in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. International Journal of Immunopathology and Pharmacology 2009 22 2 543 546 2-s2.0-67650477221
22. Giannitti C., Fineschi I., Frediani B., Fioravanti A., Galeazzi M., Efficacy and safety of tocilizumab combined with cyclosporine A in a patient with rheumatoid arthritis and concomitant chronic hepatitis C virus infection. Clinical and Experimental Rheumatology 2013 31, article 816